Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.
Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A, Sigouros M, van Besien K, Horwitz S, Rutherford SC, Mulvey E, Revuelta MV, Xiang J, Alonso A, Melnick A, Elemento O, Inghirami G, Leonard JP, Cerchietti L, Martin P. Ruan J, et al. Among authors: sigouros m. Blood. 2023 May 4;141(18):2194-2205. doi: 10.1182/blood.2022018254. Blood. 2023. PMID: 36796016 Free PMC article. Clinical Trial.
Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.
Conteduca V, Ku SY, Fernandez L, Dago-Rodriquez A, Lee J, Jendrisak A, Slade M, Gilbertson C, Manohar J, Sigouros M, Wang Y, Dittamore R, Wenstrup R, Mosquera JM, Schonhoft JD, Beltran H. Conteduca V, et al. Among authors: sigouros m. NPJ Precis Oncol. 2021 Sep 13;5(1):84. doi: 10.1038/s41698-021-00227-7. NPJ Precis Oncol. 2021. PMID: 34518634 Free PMC article. No abstract available.
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.
Conteduca V, Ku SY, Fernandez L, Dago-Rodriquez A, Lee J, Jendrisak A, Slade M, Gilbertson C, Manohar J, Sigouros M, Wang Y, Dittamore R, Wenstrup R, Mosquera JM, Schonhoft JD, Beltran H. Conteduca V, et al. Among authors: sigouros m. NPJ Precis Oncol. 2021 Aug 12;5(1):76. doi: 10.1038/s41698-021-00211-1. NPJ Precis Oncol. 2021. PMID: 34385567 Free PMC article.
Patient derived organoids to model rare prostate cancer phenotypes.
Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, Churakova Y, Cheung C, Deonarine LD, McNary TJ, Rosati R, Tagawa ST, Nanus DM, Mosquera JM, Sawyers CL, Chen Y, Inghirami G, Rao RA, Grandori C, Elemento O, Sboner A, Demichelis F, Rubin MA, Beltran H. Puca L, et al. Among authors: sigouros m. Nat Commun. 2018 Jun 19;9(1):2404. doi: 10.1038/s41467-018-04495-z. Nat Commun. 2018. PMID: 29921838 Free PMC article.
Clinical features of neuroendocrine prostate cancer.
Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JM, Elemento O, Nanus DM, Tagawa ST, Ballman KV, Beltran H. Conteduca V, et al. Among authors: sigouros m. Eur J Cancer. 2019 Nov;121:7-18. doi: 10.1016/j.ejca.2019.08.011. Epub 2019 Sep 13. Eur J Cancer. 2019. PMID: 31525487 Free PMC article.
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GM, Orlando F, Fedrizzi T, Ku SY, Dann E, Alonso A, Mosquera JM, Sboner A, Xiang J, Elemento O, Nanus DM, Tagawa ST, Benelli M, Demichelis F. Beltran H, et al. Among authors: sigouros m. J Clin Invest. 2020 Apr 1;130(4):1653-1668. doi: 10.1172/JCI131041. J Clin Invest. 2020. PMID: 32091413 Free PMC article. Clinical Trial.
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.
Conteduca V, Ku SY, Puca L, Slade M, Fernandez L, Hess J, Bareja R, Vlachostergios PJ, Sigouros M, Mosquera JM, Sboner A, Nanus DM, Elemento O, Dittamore R, Tagawa ST, Beltran H. Conteduca V, et al. Among authors: sigouros m. Mol Cancer Ther. 2020 May;19(5):1157-1164. doi: 10.1158/1535-7163.MCT-19-0926. Epub 2020 Mar 3. Mol Cancer Ther. 2020. PMID: 32127465 Free PMC article.
Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.
Beg S, Bareja R, Ohara K, Eng KW, Wilkes DC, Pisapia DJ, Zoughbi WA, Kudman S, Zhang W, Rao R, Manohar J, Kane T, Sigouros M, Xiang JZ, Khani F, Robinson BD, Faltas BM, Sternberg CN, Sboner A, Beltran H, Elemento O, Mosquera JM. Beg S, et al. Among authors: sigouros m. Transl Oncol. 2021 Jan;14(1):100944. doi: 10.1016/j.tranon.2020.100944. Epub 2020 Nov 12. Transl Oncol. 2021. PMID: 33190043 Free PMC article.
35 results